M45.0
Conditions
Interventions
Group 1: Patients with confirmed axial spondylarthritis (axSpA), who in addition to a 7-day multimodal rheumatologic complex therapy receive sl-wIRAR (2 back irradiations with sl-wIRAR daily for 6 day
Sponsors
Campus Kerckhoff der Justus-Liebig-Universität Gießen
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: All patients aged 18 to 80 with axSpA fulfilling the ASAS classification criteria on stable non-steroidal anti-inflammatory drug (NSAID) therapy or stable non-pharmacological therapy for at least 4 weeks priorly with moderate disease activity defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of 4 to 7 receiving an inpatient 7-day multimodal rheumatologic complex treatment (MRCT) were eligible.
Exclusion criteria
Exclusion criteria: Patients are excluded if they receive glucocorticoids (systemic or local) and/or conventional synthetic (cs)- and/or biologic (b-) disease-modifying antirheumatic drugs (DMARDs) treatment or due to disease manifestation have now the need for any of these treatments. Patients with contraindications to hyperthermia (e.g. sensitivity disorders, heat intolerance, therapy with photosensitizing drugs, heat urticaria, new manifested hematomas, severe (chronic) kidney injury or severe (chronic) heart failure or acute infections are excluded as well. Lack of German knowledge. Lack of adherence.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in pain level measured on a numerical ranking scale (0 to 10) before (baseline, T0) and after 6 days of asl-wIRAS therapy (T1) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) before (day 0) and after (day 6) a 6-day asl-wIRAS therapy. Change in Bath Ankylosing Spondylitis Disease Functional Index (BASFI) before and after 6 days of asl-wIRAS therapy. Change in Bath Ankylosing Spondylitis Patient Global Score (BAS-G) before and after 6 days of asl-wIRAS therapy. Change in the level of Tumour Necrosis Factor-alpha, Interleukin 1, -6 and -10 before and after 6 days of asl-wIRAS therapy. Change of painlevels measured on a numeric Rating scale (0-10) between baseline (T0), 2 days of internvention (T2), 5 days of Intervention (T3) and after Trial completion (T1). Pain will be assessed before and after a Intervention at those time Points. | — |
Countries
Germany
Contacts
Public ContactPhilipp Klemm
Campus Kerckhoff der Justus Liebig Universität Giessen, Abt. für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin
Outcome results
None listed